Sign In
5 Aug 2021 16:05
Amendments to Bylaws
GAITHERSBURG, MD, August 5, 2021 - MaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT, MXCN) ("MaxCyte" or the "Company"), a leading provider of cell-engineering platform technologies, announces that it has filed amended and restated Bylaws (the "Bylaws") with the U.S. Securities and Exchange Commission on Form 8-K.
In line with the Company's previous announcement on 29 July 2021 relating to the listing of the Company's common stock on Nasdaq, certain rights have been incorporated into the Bylaws which the Company believes stockholders would expect to see in a company whose shares are admitted to trading on a U.S. listed exchange.
Copies of this document can found on the company's website, and be downloaded via the following link:
https://investors.maxcyte.com/static-files/efd81a4a-09b7-4d8f-a773-d6c1693fa29a
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialisation of next-generation cell therapies. The company's existing customer base ranges from large biopharmaceutical companies -- including 20 of the top 25 pharmaceutical companies based on 2020 global revenue -- to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers that allow for more than 75 clinical programmes. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.
MaxCyte Contacts:
MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer
|
+1 301-944-1660 |
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
Joint Corporate Broker Numis Securities Limited James Black / Duncan Monteith / Matthew O'Dowd
|
+44 (0)20 7260 1000 |
Joint Corporate Broker Stifel Nicolaus Europe Limited Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams
|
+44 (0)20 7710 7600
|
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh
|
+44 (0)203 709 5700 maxcyte@consilium-comms.com
|
US IR Adviser Gilmartin Group David Deuchler, CFA |
+1 415-937-5400 ir@maxcyte.com
|
Forward-Looking Statements
Certain statements made in this press release are forward-looking statements including with respect to the admission of the shares of common stock to trading on AIM. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including if the shares of common stock are not admitted to trading on AIM or admission is delayed or if there are adverse market or economic conditions. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this press release. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Follow the stocks
